ISCT Join as Strategic Partners for Phacilitate Trade Mission to Japan and South Korea
ISCT confirmed as strategic partner for Phacilitate's trade mission to Asia, June 2018
LONDON, June 11, 2018 (Newswire.com) - Phacilitate announces the ISCT (International Society for Cellular Therapy) as strategic partners for the upcoming trade mission to Asia. ISCT will be providing unique agenda content and bringing crucial industry players to the trade mission. This partnership solidifies both organisation’s commitment to sustainable growth and commercialisation for the advanced therapy industry.
“As a global organization, ISCT is pleased to partner with Phacilitate’s trade mission to Asia in service of ISCT’s commitment to grow the cell and gene therapy industry in the region. By bridging regions to enable global business partnerships, this facilitates the development of cell and gene therapies for the ultimate benefit of patients worldwide. As part of the ISCT 2019 Road to Melbourne, this partnership will emphasize ISCT’s strategic focus on the Asia-Pacific Region leading into the ISCT 2019 Annual Meeting in Melbourne, Australia, May 29 – June 1, 2019.” – Miguel Forte, CEO at Zelluna Immunotherapy, Chair of Commercialization Committee at ISCT
This trade mission to Asia covers two cities in five days. The first stop is Seoul, South Korea followed by Tokyo, Japan. Some of the esteemed speakers include Kunihiko Suzuki of MEDINET Co., Akihiro Shimosaka of ACTO, major biotechs including Kolon Life Science, ViroMed and Medipost, and key government departments such as the Korean Ministry of Food and Drug Safety.
Speaking to Kunihiko Suzuki, Vice Chairman and Member of the Board, MEDINET Co., Ltd he remarks; “The very first Trade Mission to Asia by Phacilitate will provide excellent opportunities to learn the business environment for the non-Japanese and non-Korean organizations who have intention to expand their business in these regions. In addition, the participants of the trade mission will be able to establish their business presence in Japan, utilizing the benefit of two regulatory tracks, the PMD Act and ASRM and reach successful operations with support from highly experienced players such as CROs, CDMOs, big pharma and other supporting industry players in Japan.”
Experts from North American and European organisations are also supporting the trade mission. Anthony Davies, Ph.D., CEO of Dark Horse Consulting added, “As the first and only global consulting practice focused on CMC for cell and gene therapy, Dark Horse thoroughly endorses the intent of this trade mission. We also welcome the ISCT’s participation as a strategic partner. I look forward both to presenting our approach to navigating the challenges of manufacturing and regulating ATMPs, but also to listening to the concerns and aspirations of the Pacific Rim’s pioneers and participants in this field.”
Being Phacilitate’s first step into the Asian market, Michael Adeniya, Director of Advanced Therapies at Phacilitate commented, “This collaboration opens the way for pharma, biotech and technology enablers amongst ISCT’s members to make the first steps in learning more about opportunities in Japan and South Korea; two highly innovative and exciting regions for cell therapy development.”
Phacilitate Trade Mission: Navigating Asia
26 June 2018 – Grand Intercontinental Seoul, South Korea
28 June 2018 – Park Hyatt Tokyo, Japan
This is Phacilitate’s first step into the Asia market for the advanced therapies industry. The trade mission will be followed up with a conference in Shanghai, Advanced Cell Therapy Shanghai Summit 2018 (ACTSS2018) in October.
Source: Phacilitate, a Clarion Events company